Voluntary early-review initiative shifts to preventive manufacturing quality oversight
The FDA launched a new “Pre-Check” voluntary program allowing pharmaceutical manufacturers to undergo proactive quality systems reviews before production begins, rather than only traditional post-production facility inspections.
The preventive approach aims to identify potential quality issues early in the manufacturing process, reducing inspection delays and bolstering supply chain resilience for essential medicines.
Supply Chain Security: The initiative addresses growing concerns about drug shortages that have plagued generic medications and critical therapies. By shifting from reactive to preventive oversight, the FDA hopes to ensure more reliable medicine availability while maintaining safety standards.
The PreCheck pilot represents broader regulatory modernization efforts to adapt oversight approaches to contemporary manufacturing challenges and supply chain complexities.
